Found 70 clinical trials
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)
- 314 views
- 24 Nov, 2020
- 1 location
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.
- 0 views
- 24 Jan, 2021
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH
- 0 views
- 04 Mar, 2021
- 1 location
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval
- 0 views
- 25 Jan, 2021
- 2 locations
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm
There is a need to determine actual compliance of direct oral anticoagulants and how to improve this to reduce risk of stroke in patients with atrial fibrillation. Mobile health tools have been implemented world-wide in various patient populations as means of reducing cardiovascular risk and improving disease management. Results of …
- 4 views
- 08 Apr, 2021
- 1 location
-
Phase 1 trial
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
- 0 views
- 28 Mar, 2021
- 1 location
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Apixaban for Extended Anticoagulation (APIDULCIS)
with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.
- 6 views
- 27 Mar, 2021
- 1 location
-
Multi-country trial
-
Phase 4 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- 0 views
- 18 Apr, 2021
- 166 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous
- 8 views
- 05 Mar, 2021
- 120 locations
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.
- 0 views
- 25 Mar, 2021
- 4 locations